Physician profile
Joonho Park
NPI 1235576166
$3,438.07
in general payments reported to CMS, 2019-2025
18 companies · $628 in 2025
The $628 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $125 · 2021: $149 · 2022: $481 · 2023: $1,070 · 2024: $985 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,683 · Education: $1.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,682.92 |
| Education | $1.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $517.74 | 2022-2025 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $336.59 | 2022-2024 | Jesduvroq, Benlysta |
| Otsuka America Pharmaceutical, INC. | $332.37 | 2020-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $302.78 | 2022-2025 | |
| Horizon Therapeutics Plc | $287.92 | 2021-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $281.31 | 2024-2025 | |
| Amgen INC. | $278.60 | 2023-2025 | Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $250.72 | 2023-2025 | |
| Baxter Healthcare | $249.43 | 2023 | Renal - Pd |
| Aurinia Pharma U.S., INC. | $237.59 | 2023-2024 | Lupkynis |
| Calliditas Therapeutics US INC. | $135.73 | 2023-2024 | Tarpeyo |
| Vifor Pharma, INC. | $61.56 | 2024 | Veltassa |
| Alexion Pharmaceuticals, INC. | $55.92 | 2024-2025 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.48 | 2024 | Jardiance |
| Apellis Pharmaceuticals, INC. | $22.31 | 2025 | Empaveli |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cormedix INC. | $18.59 | 2025 | |
| Opko Pharmaceuticals, LLC | $18.48 | 2024 | Rayaldee |
| Ardelyx, INC. | $17.95 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joonho Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.